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Background/Aims
There has been a controversy regarding the usefulness of biofeedback therapy for functional constipation or fecal incontinence. 
This study was performed to investigate the long-term clinical efficacy of biofeedback therapy.
Methods
Sixty-four patients with constipation or fecal incontinence received biofeedback therapy for 4 weeks. Symptom improvements 
were evaluated immediately after the completion of biofeedback therapy and during the follow-up period of about 12 to 64 
months.
Results
Twenty-five patients in the constipation group [mean age of 52.1 years, 16 men (64.0%)] received 6.2 sessions of biofeedback 
therapy. Improvement of constipation after the completion of biofeedback therapy was as follows: major response (or im-
provement) in 3 patients (12.0%), fair in 6 (24.0%), minor in 11 (44.0%) and none in 5 (20.0%). Among 9 patients who 
showed major or fair improvement, 8 patients (88.9%) maintained the symptom improvement through the long term fol-
low-up periods. Thirty-nine patients in the fecal incontinence group [59.7 years old, 15 men (38.5%)] received 6.8 sessions of 
biofeedback therapy. Improvement of incontinence after the completion of biofeedback therapy was as follows: major im-
provement in 6 patients (15.4%), fair in 14 (35.9%), minor in 14 (35.9%), and none in 5 (12.8%). All 11 patients with major 
or fair improvement maintained the symptom improvement to the end of follow-up periods.
Conclusions
Symptom improvements after biofeedback therapy were disappointing in both the constipation and incontinence group. 
However, when the symptom improvements were classified as major or fair, the improvements continued for at least a year.  
(J Neurogastroenterol Motil 2010;16:177-185)
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Introduction
Constipation and fecal incontinence are common disorders in 
gastrointestinal area. These disorders are rarely life threatening, 
but could interfere with the quality of life and on individuals’ 
self-image. Biofeedback therapy has been introduced as a method 
to treat these functional gastrointestinal disorders, especially for 
functional fecal incontinence and constipation by pelvic dyssy-
nergia. This treatment modality has been reported to be effec-
tive,
1-5 although there have been arguments over the studies on 
biofeedback therapy which were sometimes not controlled and 
had methodological problems.
Constipation is a common disorder with a prevalence of 
2-27% in adults.
6,7 Most of these patients could be treated with 
conservative treatments such as high fiber diet and/or laxatives. 
However patients with severe constipation who do not respond to 
medications seek for further medical care. Biofeedback therapy 
has been effective for constipation by pelvic floor dyssynergia 
with the success rates of 60 to 80%.
8,9 The biofeedback therapy is 
usually not effective for slow transit constipation. However, in 
slow transit constipation with pelvic floor dyssynergia, so-called 
mixed-type functional constipation, it has been effective as it is in 
normal transit constipation.
10 Some investigators insisted bio-
feedback therapy to show clinical benefits even with slow transit 
constipation.
11,12 In a recent controlled long-term follow-up 
study, the clinical benefits of biofeedback therapy in patients with 
pelvic floor dyssynergia were maintained for a long time.
8-10,13
Fecal incontinence could be defined as an involuntary pas-
sage of fecal materials after at least 4 years of age.
14 The preva-
lence of fecal incontinence is 2 to 17% and has been reported to 
increase among women, aged, and disabled.
15 Although fecal in-
continence is not a life threatening disorder, it could lead to vari-
ous social and psychological problems. Choosing treatment strat-
egy is based on the specific cause of fecal incontinence. When 
constipation occurs by a trauma to the anal sphincters during an 
obstetric procedure, or a surgical procedure, surgical modality is 
the first choice of treatment. The surgical treatment is shown to 
be highly effective in the short-term follow-up studies, whereas 
the results of long-term follow-up were questionable.
16-18 When 
conservative treatment fails or when surgical correction is not 
amenable, other therapeutic modalities are needed. Biofeedback 
therapy is a non-invasive and easily feasible option which has 
been used for fecal incontinence over several decades. Numerous 
published studies support it as the first choice of treatment for fe-
cal incontinence.
19,20 These studies have reported a success rate of 
about 70% (between 40 to 100%).
1,21 However, in a recently 
randomized-controlled study, biofeedback therapy was not more 
helpful than supportive cares, such as life-style modification, 
drug treatment, or emotional support.
22  Furthermore, in-
strumental feedback as well as non-instrumental feedback such as 
digital guidance could not prove any additional benefit of bio-
feedback therapy in a randomized-controlled trial.
23 A well-de-
signed controlled study is needed to clarify the efficacy of bio-
feedback therapy in patients with fecal incontinence. 
The aim of this study was to evaluate both the short-term and 
long-term efficacy of biofeedback therapy, and to identify the 
predicting variables associated with success of the treatment in a 
single center in South Korea.
Materials and Methods
1. Subjects 
Sixty-four patients with constipation or incontinence were 
consecutively enrolled in Seoul National University Bundang 
Hospital from June 2003 to January 2008. Twenty-four patients 
had constipation and 39 had fecal incontinence. Patients who 
completed less than 4 biofeedback sessions were excluded from 
the analysis.
2. Methods
Detailed medical history was taken to evaluate the duration of 
symptoms including any previous operation or trauma history. 
Before the biofeedback therapy, the physiological parameters 
were evaluated by anorectal manometry, balloon expulsion test 
and colonic transit testing. For the patients with fecal incon-
tinence, transanal ultrasonography was performed to assess path-
ophysiologic status of the anal sphincter. 
1) Anorectal manometry with balloon expulsion test
Before anorectal manometric evaluation, bowel preparation 
was performed by 2 pills of dulcorax suppository. Anorectal func-
tion testing was performed in the left-lateral position with the hips 
flexed to 90
o. Anorectal manometry was performed using the wa-
ter-perfusion technique with an 8-channel Micro Tip catheter 
(Medtronic) connected to a perfusion pump in the left-lateral 
position. The physiological parameters included the anal canal 
resting pressure, squeezing pressure, compliance, defecation in-
dex, resting and squeezing vectogram, and rectoanal inhibitory 
reflex. Rectal sensation was assessed by the inflation of a latex bal-Clinical Efficacy of Biofeedback Therapy
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loon with an air flow of 1 mL per second, and the threshold vol-
umes for the first minimal sensation, desire to defecate, urge, and 
maximal tolerance were determined. The balloon expulsion test 
was carried out with 50 mL water filled balloon in the following 
order: the catheter was lubricated and inserted to the rectum, and 
then the balloon was filled with a 50 mL of water at room 
temperature. The patients were instructed to sit on a commode 
chair in a usual defecation position and to pass out the balloon. 
After waiting for 5 minutes, patients who could not pass the bal-
loon across the anal canal were considered to have failed the bal-
loon expulsion test.  
2) Colon transit time
The colon transit time was measured using radio-opaque 
markers (Kolomark
TM, M.I.Tech., Pyongtaik, Korea). The sub-
jects ingested one capsule containing 20 radio-opaque markers in 
the morning at 24-hour intervals for three consecutive days; 2 
simple abdominal radiographs in the supine position were ob-
tained on day 4 and day 7. Localization of the radio-opaque 
markers was determined by identifying the relations to landmarks 
of bony structure.
24 That is, the markers located to the right side 
of the vertebral spinous processes above a line from the fifth ver-
tebra to the right pelvic outlet were assigned to the right colon, 
the markers to the left of the vertebral spinous processes and 
above an imaginary line from the fifth lumbar vertebra to the an-
terior superior iliac crest were assigned to the left colon, and the 
markers inferior to a line from the pelvic brim on the right and 
the superior iliac crest on the left were considered to locate in the 
recto-sigmoid colon and rectum. The markers were counted by 
one experienced gastrointestinal radiologist (K.L.) and total and 
segmental colon transit times were calculated as 1.2 times the sum 
of the markers on the entire or a segment of colon.
25,26 
3) Transanal ultrasound
Twenty-two patients were evaluated with a transducer, which 
was protected by a rigid plastic anal cone, encased in a disposable 
condom, and inserted with the aid of lubricant. This examination 
was carried out in the left-lateral position, without anorectal 
preparation. An endosonic 360
o axial transducer was used to 
identify the anal cushion, as well as the internal and external anal 
sphincter (IAS and EAS, respectively). The IAS was defined as a 
homogenous, hypoechoic circular band that followed the mucosa 
and submucosa of the anal canal. Sphincter integrity was also de-
termined by slow motion of the probe through the canal. The anal 
cushion and IAS thickness were determined in the middle anal 
canal in the ventral, dorsal, left and right lateral sphincter direc-
tions, as shown by the electronic cursor on the monitor. Patients 
with defect on the IAS or EAS were defined as having pathology.
3. Biofeedback therapy and clinical assessment
Biofeedback therapy was carried using the surface electro-
myography (EMG) method using a visual biofeedback system 
(Orion, Platinum, SRS Medical Systems, Inc., Redmond, WA, 
USA) and perianal sensor (Perry, Elan, SRS medical Systems, 
Redmond, WA, USA). Electrodes were attached to the lower ab-
domen and acryl plug was inserted into the anal canal. The pa-
tient watched a computer monitor displaying amplified, filtered 
EMG activity. The visual feedback was provided by observing 
changes in pressure activity on the computer monitor. 
Biofeedback therapy was planned for total of 10 sessions with 3 
sessions per week during the first 2 weeks and 4 sessions during 
the last week. Sixty-minute biofeedback training session was per-
formed at first and 30-minute session was performed from the 
second session. Each biofeedback training session was performed 
while the patient covered with a sheet and sitting on a chair to 
simulate defecation postures. In the biofeedback session for con-
stipation, the patient was instructed to relax, squeeze, or strain 
gently for a series of 10-second trials. The therapist explained the 
appropriate EMG feature and therapeutic target. In the biofeed-
back session for fecal incontinence, the patient was instructed to 
squeeze and relax the anal sphincters repeatedly along with ob-
serving changes in pressure activity on a monitor screen. All pa-
tients were trained to perform pelvic exercise, modulate the habits 
of defecation, and modify the diet by verbal or video instructions 
during biofeedback sessions. The short-term clinical efficacy was 
measured immediately after the completion of biofeedback ther-
apy and long-term efficacy was assessed according to the final tel-
ephone interview. The symptom responses categorized into 4 
types are as follows: major improvement (more than 80% of 
symptom resolution), fair improvement (symptoms remained less 
than 50%), mild improvement (symptoms remained for more 
than 50%), and none (unresponsive to the biofeedback therapy). 
Then, the statistical analysis was performed by 2 groups: res-
ponder with fair or major subgroup and non-responder with none 
or mild subgroup. 
4. Statistical methods
All data are reported as means ± standard deviation. 
Chi-square and Mann-Whitney U tests were used according to 
categorical or numeric data. A general linear model was used to 
compare the differences of anorectal function parameters between 
2 examinations performed before and after biofeedback therapy. Byoung Hwan Lee, et al
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Table 1. Baseline Characteristics of the Patients Before Biofeed-
back Therapy
Constipation Incontinence 
(n = 25) (n = 39)
Age (yr, mean ± SD)   52.1 ± 18.6 59.7 ± 16.7
Gender
Male (%)        16 (64)     15 (38.5)
Female (%)          9 (36)     24 (61.5)
Bowel frequency     2.5 ± 1.8/wk   4.8 ± 2.1/day
Symptom duration  166.4 ± 160.3 39.3 ± 58.3
 (mo)
Follow-up (mo)   49.6 ± 12.0 34.5 ± 13.8
Table 2. Characteristics of Patients With Constipation at the Initial
Enrollment and Comparison Based on the Response to Bio-
feedback Therapy 
Responder
a Non-responder
b p-value
Number (%)        9 (36)       16 (64)
Gender           3/6         13/3 0.031
 (male/female)
Age (yr)    58.8± 7.9   48.3 ± 21.8 0.552
Bowel frequency      2.3 ± 1.7     2.6 ± 1.9 0.740
 (/wk)
c
Symptom duration  240.4 ± 212.6 126.9 ± 113.9 0.428
 (mo)
Biofeedback therapy      7.2 ± 2.8     6.6 ± 2.9 0.527
 (sessions)
aMajor improvement (more than 80% symptom resolution) or fair improvement
(symptoms less than 50%), 
bMild improvement (symptoms remained more than
50%) or none (unresponsive to the biofeedback therapy), 
cFrequency of 
defecation during 1 week. 
Bold style indicates statistical significance.
A p-value of less than 0.05 was considered statistically significant. 
Data were analyzed using the SPSS statistical software package 
(SPSS 15.0 for Windows, SPSS Inc., Chicago, IL, USA).
Results
1. Characteristics of patients
Total of 64 patients were enrolled; 25 patients had con-
stipation (39.1%) and 39 patients had fecal incontinence (60.9%) 
(Table 1). The mean age was 52.1 ± 18.6 years in the con-
stipation group and 59.7 ± 16.7 years in the fecal incontinence 
group. There were more males (64.0%) than females (36.0%) in 
the constipation group and more females (61.5%) than males 
(38.5%) in the fecal incontinence group (p = 0.046). The bowel 
movement frequency was 2.5 ± 1.8 per week in the constipation 
group and 4.8 ± 2.1 per day in the fecal incontinence group 
(Table 1). 
2. Clinical efficacy of biofeedback therapy
The mean follow-up period was 49.6 ± 12.0 months in the 
constipation group and 34.5 ± 13.8 months in the incontinence 
group, respectively. Improvement of constipation after com-
pletion of biofeedback therapy was noted by the following order: 
major improvement in 3 patients (12%), fair in 6 (24%), minor in 
11 (44%), and none in 5 (20%). Among 9 patients who showed 
major or fair improvements (responder group), 8 patients 
(88.9%) maintained the symptom improvements through the 
long-term follow-up periods. Among 39 incontinence patients, 
improvements of incontinence after completion of biofeedback 
therapy are as follows: major in 6 patients (15.4%), fair in 14 
(35.9%), minor in 14 (35.9%), and none in 5 (12.8%). Among 11 
patients who showed major or fair improvements (responder 
group), all maintained the symptom improvements through the 
long-term follow-up periods. 
3. Biofeedback therapy sessions
The average number of sessions for biofeedback therapy was 
6.2 times in the constipation group and 6.8 times in the incon-
tinence group. No significant difference was observed among the 
responder group in regard to the frequency of biofeedback ses-
sions in both the constipation and incontinence patients.
4. Anorectal physiological parameters 
Analysis was performed between the responder and non-res-
ponder group in either constipation or incontinence group. In the 
constipation group, no significant differences were found be-
tween the responder and non-responder group at baseline with 
regard to demographic variables such as age, symptom duration, 
and bowel frequency (Table 2). However, female responded 
more fairly to biofeedback therapy than male (p = 0.031) (Table 
2). Also there were no significant differences between the res-
ponder and non-responder group with regard to the physiologic 
parameters such as resting pressure and squeezing pressure, al-
though the defecation index was lower in the non-responder 
group (p = 0.041) (Table 3). There were no differences in the 
minimal volume, urgent volume and critical volume in measuring 
the rectal sensory threshold, while the desire to defecate volume 
was smaller in the responder group. No differences in colon 
transit time and balloon expulsion test before biofeedback therapy Clinical Efficacy of Biofeedback Therapy
181 Vol. 16, No. 2 April, 2010 (177-185)
Table 3. Physiological Parameters of the Patients With Cons-
tipation at the Initial Enrollment and Comparison Based on the 
Response to Biofeedback Therapy
Responder
a Non-responder
b
                        p-value
(n = 9) (n = 16)
Anorectal manometry findings
Resting pressure    52.2 ± 30.2   48.6 ± 13.8 0.789
 (mmHg)
Squeezing pressure  137.6 ± 61.5 127.2 ± 55.3 0.640
 (mmHg)
Defecation index
c   2.86 ± 3.46   1.03 ± 0.81 0.041
Minimal volume    33.3 ± 14.1   44.6 ± 18.5 0.147
 (mL)
Desire to defecate    71.1 ± 10.5   88.3 ± 18.5 0.019
 volume (mL)
Urgent volume  127.1 ± 19.8 150.0 ± 49.3 0.402
 (mL)
Critical volume  162.2 ± 23.3 205.0 ± 89.0 0.423
 (mL)
Colon transit time   61.3 ± 49.9   62.2 ± 38.0 0.910
 (hr)
Balloon expulsion test         7/2         10/3 0.962
 (success/failure)
aMajor improvement (more than 80% symptom resolution) or fair improvement
(symptoms less than 50%), 
bMild improvement (symptoms remained more than
50%) or none (unresponsive to the biofeedback therapy), 
cRectal pressure during
straining/anal residual pressure during straining.
Bold style indicates statistical significance.
Table 4. Characteristics and Physiological Parameters of Patients 
With Fecal Incontinence at the Initial Enrollment and Comparison
Based on the Response to Biofeedback Therapy 
Responder
a Non-responder
b
                         p-value
(n = 20) (n = 19)
Number (%)     20 (51.3)     19 (48.7)
Gender         6/14        9/10 0.265
 (male/female)
Age (yr)   62.0 ± 15.5 57.1 ± 18.1 0.412
Bowel frequency      5.1 ± 2.1   4.4 ± 2.1 0.290
 (/day)
Symptom duration    31.6 ± 50.2 45.3 ± 65.1 0.365
 (mo)
Biofeedback therapy      6.5 ± 2.9   5.7 ± 2.6 0.579
 (sessions)
Anorectal manometry
Resting pressure    27.6 ± 14.3 24.2 ± 15.1 0.366
 (mmHg)
Squeezing pressure  125.4 ± 48.9 91.2 ± 43.7 0.027
 (mmHg)
Minimal sensory    30.5 ± 13.9 34.1 ± 20.9 0.749
 volume (mL)
aMajor improvement (more than 80% symptom resolution) or fair improvement
(symptoms less than 50%), 
bMild improvement (symptoms remained more than
50%) or none (unresponsive to the biofeedback therapy).
Bold style indicates statistical significance.
Table 5. Changes of Manometric Parameters Before and After Biofeedback Therapy in Patients With Fecal Incontinence 
Before biofeedback After biofeedback p-value
Resting pressure (mmHg) Responder (n = 7)   32.7 ± 14.4   22.8 ± 15.0 0.171
Non-responder (n = 6)   19.6 ± 8.5   18.1 ± 16.2
Squeezing pressure (mmHg) Responder (n = 7) 118.2 ± 23.8 142.7 ± 35.7 0.019
Non-responder (n = 6)   90.8 ± 37.1   79.8 ± 38.2
Minimal volume (mL) Responder (n = 7)   25.7 ± 9.7   33.3 ± 16.3 0.235
Non-responder (n = 6)   25.0 ± 9.2   34.2 ± 15.1
Bold style indicates statistical significance.
were noted (Table 3). 
In the fecal incontinence group, there were no significant dif-
ferences between the responder and non-responder group with 
regard to the physiological parameters; with the exception on the 
squeezing pressure before biofeedback therapy (Table 4). The 
responder group showed higher squeezing pressure than the 
non-responder group (p = 0.027).
Follow-up anorectal manometry test was performed in 3 pa-
tients of the constipation group and 13 patients of the incontinence 
group after completion of biofeedback therapy. Adequate analysis 
for the physiological parameters before and after biofeedback ther-
apy was not able in the constipation group due to the small sample 
size. In the incontinence group, the squeezing pressure increased 
significantly after biofeedback therapy in the responder group as 
opposed to the non-responder group. There were no significant 
differences in the resting pressure and minimal sensory volume 
before and after biofeedback therapy (Table 5).
5. Transanal ultrasound
For the incontinence group, the status of anal sphincters was Byoung Hwan Lee, et al
182 Journal of Neurogastroenterology and Motility 
evaluated by transanal ultrasound in 27 patients. Sixteen patients 
(59.3%) had normal anal sphincters while 11 patients (40.7%) 
had anal sphincter defect or thinning. Among 16 patients with 
normal anal sphincters, 10 patients (62.5%) responded to bio-
feedback therapy, whereas 4 (36.4%) out of 11 patients with anal 
sphincter defect or thinning responded to biofeedback therapy. 
However, this result was not statistically significant (p = 0.182).  
Discussion
Biofeedback therapy has been reported to be an effective 
treatment for functional anorectal disorders such as functional 
constipation and functional fecal incontinence over the past few 
decades.
2,27 Biofeedback therapy has been accepted as the treat-
ment of choice for pelvic floor dyssyndergia and fecal incon-
tinence due to its clinical efficacy. However, there continues to be 
controversies regarding its efficacy. First, most of the clinical 
findings were found to be based on the uncontrolled studies. In 
addition, many of the studies had methodological limitations, 
such as the differences in the criteria used to define successful 
outcome, the heterogeneity of the participants studied, and the 
different variables considered during the assessments. Further-
more, some studies did not show biofeedback therapy to be more 
effective than conservative treatments especially in patients with 
fecal incontinence
22,23 and childhood functional constipation.
28 
However, the more important issue would be about the effects of 
biofeedback therapy to be maintained or not. As biofeedback 
therapy is a relatively inexpensive and non-invasive modality, it 
could be considered as the first-line therapy in patients with re-
fractory anorectal disorders when its efficacy is predicted to be 
maintained for a long time interval. 
Constipation could be classified into normal-transit con-
stipation, pelvic floor dyssynergia, slow-transit constipation, and 
the mixed type according to the results of physiological testing.
29 
In a large epidemiological study, normal transit constipation was 
the most common subtype (59%), followed by pelvic floor dys-
syndergia (25%), slow transit constipation (13%), and the mixed 
type (3%).
30 Several treatment modalities have been adopted for 
constipation such as life-style modification, medications, biofeed-
back therapy, injection of botulinum toxin,
31 sacral nerve stim-
ulation,
32 anorectal electrical stimulation,
33 and surgical treat-
ment.
34 Biofeedback therapy has been studied mainly in patients 
with pelvic floor dyssynergia. This disorder, which has also been 
called as anismus, an outlet obstruction or spastic pelvic floor syn-
drome, is a type of constipation characterized by a failure to relax 
the puborectalis muscle, the external and internal anal sphincter 
muscle during the straining for defecation. In recent controlled 
studies, Chiarioni et al.
8,10 reported biofeedback as an effective 
treatment for pelvic floor dyssynergia superior to laxatives with 
the improvement to be maintained for a long-term follow interval, 
while the effect was not found in cases of slow transit 
constipation. Biofeedback therapy was more effective than con-
servative treatments or sham feedback treatment in patients with 
pelvic floor dyssyndergia.
13 Altogether these studies suggest bio-
feedback therapy to be highly effective for pelvic floor dyssy-
nergia with the effects being long-lasting. Furthermore, some 
studies reported the effectiveness of biofeedback therapy for 
slow-transit constipation,
11,12 which was shown by the improve-
ment of cerebral cortex activity controlling colon motility.
35,36 In 
the present study, we applied biofeedback therapy for refractory 
constipation patients regardless of the constipation type. The ef-
fect of biofeedback therapy was found in 36% of constipation pa-
tients with 88.9% of the responder group maintaining the symp-
tom improvements for the long follow-up intervals. The lower 
outcome of biofeedback therapy just after the completion of bio-
feedback therapy may have originated from the broad category of 
participants including those with slow-transit constipation. 
Furthermore, defecation index, which is specific for pelvic floor 
dyssynergia,
26 was significantly lower in the non-responder 
group. Again these results could be due to the broad indication of 
biofeedback therapy with the relatively old participants in our 
study. Several studies have evaluated the variables associated with 
successful outcome.
8,10,37 Park et al.
37 reported the defecation in-
dex and pelvic floor dyssynergia as factors influencing the re-
sponse by multivariate analysis. Other investigators have sug-
gested milder constipation, less frequent abdominal pain, digital 
facilitation, slow transit, and the defecation index to be associated 
with successful outcome. But not a common specific variable 
emerged when a critical review was performed.
1 In our study, the 
rectal sensory parameters showed relatively lower pressures and 
volumes in the responder group and desire to defecate volume 
was also significantly lower in the responder group than in the 
non-responder group. In other words, the non-responder group 
showed higher minimal volume, desire to defecate volume, ur-
gent volume, and critical volume than the responder group and 
the difference in desire to defecate volume was statistically 
significant. Furthermore, similar trend was observed in the fol-
low-up anorectal manometry test after completion of biofeedback 
therapy. Urgent volume after biofeedback therapy was statisti-
cally higher in the non-responder group (180 mL vs. 140 mL, pClinical Efficacy of Biofeedback Therapy
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= 0.031). Rectal hyposensitivity is associated not only with func-
tional GI disorders but also with the response to biofeedback 
therapy, which is more effective in patients with relatively pre-
served anorectal physiology. Recently, rectal hyposensitivity has 
been considered as a causal factor for functional GI disorders and 
some authors are trying therapeutic modalities such as electrical 
stimulation.
33,38 Chang et al.
33 reported the efficacy of electrical 
stimulation to be comparable to biofeedback therapy in a sub-
group of constipation, especially in those with impaired rectal 
sensation. The pathophysiological mechanisms of rectal hypo-
sensitivity are not well-known, but some studies have shown the 
association with diminished rectal perception.
39 There were no 
specific physiologic, anatomic, or demographic variable asso-
ciated with successful outcome. 
Fecal incontinence is defined as a recurrent uncontrolled pas-
sage of fecal material which presents with a social as well as a per-
sonal hygienic problem.
40 The cause of fecal incontinence varies 
and includes abnormalities of intestinal motility, poor rectal com-
pliance, impaired rectal sensation, or weakened pelvic floor 
muscles.
2 In patients with muscle or nerve damage due to disease 
pathology, obstetric injuries, or rectal prolapse, treatment must be 
determined based on the cause.
2 However, the fact that the path-
ophysiology and physiological dysfunction to coexist as syner-
gistic factors may make biofeedback therapy a useful first-line 
therapy. A few studies showed biofeedback therapy to be se-
lectively effective in patients who were initially considered for 
surgery.
41,42 In our study, 11 patients were identified with anal 
sphincter injury by transanal ultrasound; 6 patients showed thin-
ning of anal sphincter, 5 patient showed defect of anal sphincter. 
Out of 6 patients showing the thinning, 3 patients responded to 
biofeedback therapy and among 5 patients showing the defect, 
only one patient responded to biofeedback therapy. The generally 
low response rate of biofeedback therapy may lead to surgical mo-
dality, but patients who do not have severe damage could be con-
sidered as candidates for biofeedback therapy. Demographic fea-
tures of fecal incontinence are more common in women than men  
and increase with age in adults, probably due to the pelvic 
changes and trauma associated with childbirth.
43 Women have a 
better response than men, for reasons not yet determined.
44 In our 
study, female patients (24, 61.5%) were more prevalent than male 
(15, 38.5%) in the incontinence group, but no statistical differ-
ence was noted with regard to the clinical efficacy. Although bio-
feedback therapy has been reported to be an effective treatment 
for fecal incontinence for over the past 30 years, the studies per-
formed are lacking in adequately controlled data.
1,2 Recent 
randomized, controlled, and blinded trials have not shown the su-
periority of biofeedback therapy compared to standard care sup-
plemented by advice and education.
22,45 In addition, non-in-
strumental feedback using simple digital insertion was equally as 
effective as instrumental biofeedback therapy.
23 In spite of these 
limitations of biofeedback therapy, recent studies have concluded 
biofeedback-induced improvement to be maintained for a long 
time interval after treatment.
21,22 There continues to be con-
troversy on the use of biofeedback therapy for fecal incontinence, 
which may account for the reluctance in clinical use and the need 
for well-designed controlled studies to assess its efficacy. In our 
study, the clinical effect of biofeedback therapy was observed in 
20 patients (51.3%) among 39 participants. Similar to other re-
cent data, all patients who responded to biofeedback therapy have 
maintained the improvement on the most recent follow-up by tel-
ephone interview in the present study. Again the low response 
rate in the present study may have been due to the broad range of 
participants including anal sphincter defects caused by surgical 
procedures. Variables which tend to negatively affect the clinical 
outcome were reported to be the underlying neurological impair-
ment and the heterogeneity of study group,
1 as in our data. No 
objective factors has been identified in a critical review of many 
studies to date.
1 Some studies have shown the improvement of 
manometric parameters after biofeedback therapy.
23,46 However, 
most of the data points to inconsistencies between subjective im-
provement and objective parameters such as manometric 
changes.
47 In our study, a high anal squeezing pressure was an in-
dicator for a good response (p = 0.027). In addition, the res-
ponder group showed increases in the anal squeezing pressure af-
ter biofeedback therapy (p = 0.019). These results in the incon-
tinence group suggest patients with mild anorectal pathophysiol-
ogy to present with a good response to biofeedback therapy as in 
the constipation group. We could not find any other objective pa-
rameters than the anal squeezing pressure which correlated with 
the clinical efficacy evaluated by the anorectal manometry after 
completion of biofeedback therapy.
In our study, there are several methodological problems. 
First of all, we did not use the Rome II or Rome III criteria. 
Instead, biofeedback was performed in patients with either con-
stipation or incontinence who did not respond to conservative 
medical therapy such as life-style modifications and medications. 
Second, the criteria for the evaluation of clinical efficacy were 
rather subjective. Successful outcome was defined depending on 
the patient’s subjective report. Third, follow-up periods were 
variable. However, as biofeedback therapy has not been estab-Byoung Hwan Lee, et al
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lished as a standard therapy for constipation or incontinence and 
the response rate has been known to be inconsistent, it might be a 
valuable attempt to analyze the efficacy of biofeedback therapy in 
the crude patient group and share the experience of one 
institution.  
In conclusion, biofeedback therapy in our study showed low 
successful outcome, but the clinical efficacy was maintained for a 
long time once the patients responded to the therapy. As patients 
with mild anorectal pathophysiology show good response to bio-
feedback therapy, it must be considered as the first therapeutic 
modality for functional anorectal disorders before they advance 
into more serious cases. 
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